Stryker (SYK) has received 510(k) clearance from the U.S. Food and Drug Administration for Sonopet 3, a new ultrasonic bone and soft tissue removal platform developed with extensive surgeon input.
Recent trading shows momentum picking up for Stryker, with a 1-day share price return of 3.2% and a 30-day share price return of 11.6% at a last close of US$307.08. This comes even though the 1-year total shareholder return is down 19% and the year to date share price return is down 11.8%, while the 3-year total shareholder return of 22.3% points to a stronger longer run record.
Spot fresh momentum stories beyond Stryker by scanning a hand picked group of medical and surgical equipment players in the 30 resilient stocks with low risk scores.Stryker looks like a high quality medical technology business, yet the share price has only just started to recover from a weak year. After this latest jump, is the stock already expensive or still reasonable value?
Most Popular Narrative: 1% Undervalued
Stryker’s most followed valuation story anchors fair value close to today’s market level, with the narrative fair value of $311.21 sitting just above the last close at $307.08. That framing keeps the focus on quality and durability rather than a big discount gap.
Stryker is my defensive growth anchor, a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, supported by the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.
See why 5 investors see Stryker as 1% undervalued.
Result: Fair Value of $311.21 (ABOUT RIGHT)
Still, the Stryker narrative could be shaken if hospital capital spending tightens, or if acquisitions create integration setbacks that dent profitability.
Find out about the key risks to this Stryker narrative.
Next Steps
If this mix of caution and optimism around Stryker feels familiar, consider reviewing the data now and forming your own view with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Stryker?
If Stryker has your attention, do not stop with a single opportunity. Broaden your watchlist using focused screeners that surface very different types of potential investments.
- Target underappreciated quality by reviewing the 30 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their strengths.
- Strengthen your income stream by scanning the 6 dividend fortresses that combine higher yields with characteristics aimed at more resilient payouts.
- Prioritise resilience in tougher markets by focusing on the 30 resilient stocks with low risk scores that score well on financial health and volatility.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com